Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Anker, S.; Butler, J.; Filippatos, G.; Ferreira, J.; Bocchi, E.; Böhm, M.; Brunner-la Rocca, H.; Choi, D.; Chopra, V.; Chuquiure-Valenzuela, E.; Giannetti, N.; Gómez-Mesa, J.; Janssens, S.; Januzzi, J.; González-Juanatey, J.; Merkely, B.; Nicholls, S.; Perrone, S.; Piña, I.; Ponikowski, P.; Senni, M.; Sim, D.; Špinar, J.; Squire, I.; Taddei, S.; Tsutsui, H.; Verma, S.; Vinereanu, D.; Zhang, Jian; Carson, P.; S. P. Lam, Carolyn; Marx, N.; Zeller, C.; Sattar, N.; Jamal, W.; Schnaidt, S.; Schnee, J.; Brueckmann, M.; Pocock, S.; Zannad, F.; Packer, M.

doi:10.1056/NEJMoa2107038

Public

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Shared by NobleBlocks on Aug 27, 2021 • 12:00 AM UTC

Authors:

S. Anker

J. Butler

G. Filippatos

Abstract

BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS In this double-blind tri...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!